See more : John Wiley & Sons, Inc. (WLYB) Income Statement Analysis – Financial Results
Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Entergy Mississippi, Inc. 1M BD 66 (EMP) Income Statement Analysis – Financial Results
- Companhia Energética de Minas Gerais (CMIG3.SA) Income Statement Analysis – Financial Results
- Alkaline Fuel Cell Power Corp. (PWWR.NE) Income Statement Analysis – Financial Results
- Airports of Thailand Public Company Limited (AIPUF) Income Statement Analysis – Financial Results
- Harvest Capital Credit Corporation 6.125% Notes due 2022 (HCAPZ) Income Statement Analysis – Financial Results
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 881.71K | 3.94M | 36.14M | 4.82M | 2.44M | 1.91M | 648.38K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 31.17M | 1.49M | 1.64M | 98.27K | 89.60K | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 0.00 | 0.00 |
| Gross Profit | -31.17M | -1.49M | -757.53K | 3.84M | 36.05M | -43.79M | -23.60M | -13.53M | -5.24M | -1.26M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -85.92% | 97.50% | 99.75% | -908.11% | -967.09% | -707.60% | -808.21% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.17M | 16.14M | 36.45M | 98.27M | 89.60M | 48.61M | 26.04M | 15.44M | 5.89M | 1.26M | 210.67K | 575.09 |
| General & Administrative | 13.91M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Selling & Marketing | -641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.27M | 18.70M | 20.43M | 28.48M | 23.64M | 12.96M | 8.96M | 6.46M | 3.61M | 1.39M | 346.61K | 289.05 |
| Other Expenses | -30.53M | -48.77K | 11.90M | 13.27M | 4.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.91M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Cost & Expenses | 45.08M | 34.84M | 56.87M | 126.75M | 113.25M | 61.57M | 35.00M | 21.90M | 9.50M | 2.65M | 557.28K | 827.22 |
| Interest Income | 0.00 | 0.00 | 1.83K | 1.03K | 1.23M | 982.78K | 183.11K | 477.00 | 3.42K | 2.12K | 754.00 | 59.74 |
| Interest Expense | 2.92M | 2.13M | 1.83M | 1.03M | 19.03K | 0.00 | 183.11K | 0.00 | 2.44K | 24.02K | 45.11K | 0.00 |
| Depreciation & Amortization | 640.60K | 1.49M | 1.64M | 1.69M | 1.23M | 493.94K | 255.65K | 87.66K | 43.94K | 10.41K | 754.00 | 824.15 |
| EBITDA | -44.44M | -38.73M | -54.97M | -121.69M | -76.37M | -56.25M | -32.31M | -19.90M | -8.81M | -2.64M | -556.52K | -62.81 |
| EBITDA Ratio | 0.00% | 0.00% | -6,381.74% | -3,101.40% | -212.89% | -1,178.71% | -1,332.72% | -1,040.23% | -1,358.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.08M | -39.84M | -55.99M | -122.81M | -77.10M | -56.75M | -32.56M | -19.99M | -8.85M | -2.65M | -557.28K | -824.15 |
| Operating Income Ratio | 0.00% | 0.00% | -6,350.09% | -3,119.20% | -213.33% | -1,176.78% | -1,334.43% | -1,045.56% | -1,365.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 473.99K | -2.51M | 10.35M | 11.54M | 5.65M | 1.08M | 141.20K | -13.62K | 2.95K | 106.69K | -45.07K | -62.81 |
| Income Before Tax | -44.60M | -42.35M | -45.64M | -111.27M | -71.45M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Income Before Tax Ratio | 0.00% | 0.00% | -5,176.38% | -2,826.08% | -197.69% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 13.49M | -87.84K | 35.05K | -2.30M | 1.08M | -396.86K | 13.62K | 2.44K | 24.02K | 44.36K | -62.81 |
| Net Income | -44.60M | -55.83M | -45.55M | -111.30M | -69.15M | -55.67M | -32.42M | -20.00M | -8.85M | -2.54M | -602.35K | -886.96 |
| Net Income Ratio | 0.00% | 0.00% | -5,166.42% | -2,826.97% | -191.33% | -1,154.48% | -1,328.65% | -1,046.27% | -1,365.05% | 0.00% | 0.00% | 0.00% |
| EPS | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| EPS Diluted | -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.30 | -19.38 | -14.58 | -8.47 | -3.78 | -0.70 | -3.82 |
| Weighted Avg Shares Out | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.00 |
| Weighted Avg Shares Out (Dil) | 4.33M | 4.17M | 4.10M | 2.60M | 2.13M | 1.90M | 1.67M | 1.37M | 1.05M | 672.00K | 860.06K | 232.16 |
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
Source: https://incomestatements.info
Category: Stock Reports